AmCad BioMed Corporation - Laporan Laba Rugi (TTM)

AmCad BioMed Corporation
TW ˙ TPEX
NT$ 21.65 ↓ -0.20 (-0.92%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi AmCad BioMed Corporation menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 58 64 64 66 79 86 91 89 75 62 55 53 56 65 63 64 58 53 52 44
Change (%) 10.18 0.42 3.05 19.32 8.66 6.42 -2.87 -15.77 -17.49 -10.88 -3.16 4.60 17.29 -3.75 1.21 -8.16 -9.03 -2.44 -15.85
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 21 22 22 22 24 25 26 27 26 24 23 22 22 24 24 23 22 20 20 20
Change (%) 0.94 0.30 3.46 8.69 3.10 4.49 3.56 -6.04 -7.68 -2.91 -4.23 -1.95 12.70 -0.58 -4.51 -2.46 -10.10 -1.90 0.33
% of Revenue 36.89 33.79 33.75 33.89 30.87 29.29 28.76 30.66 34.20 38.27 41.69 41.23 38.65 37.13 38.36 36.19 38.44 37.98 38.19 45.54
Gross Operating Profit 37 42 43 44 55 61 65 61 49 38 32 31 34 41 39 41 36 33 32 24
Change (%) 15.58 0.48 2.84 24.77 11.15 7.21 -5.46 -20.08 -22.58 -15.82 -2.40 9.19 20.19 -5.62 4.76 -11.39 -8.37 -2.78 -25.85
% of Revenue 63.11 66.21 66.25 66.11 69.13 70.71 71.24 69.34 65.80 61.73 58.31 58.77 61.35 62.87 61.64 63.81 61.56 62.02 61.81 54.46
SG&A 55 49 46 45 44 46 48 49 48 48 48 48 51 51 51 51 54 54 54 54
Change (%) -10.40 -5.48 -2.81 -1.63 4.62 3.69 1.86 -2.58 1.07 -0.84 0.83 5.35 -0.06 0.84 -1.01 5.81 0.14 0.02 0.20
% of Revenue 94.58 76.91 72.39 68.27 56.28 54.19 52.80 55.37 64.04 78.44 87.27 90.87 91.52 77.98 81.70 79.90 92.06 101.34 103.90 123.71
R&D 53 49 48 49 47 51 50 49 52 54 53 53 49 44 46 47 47 44 44 44
Change (%) -6.73 -3.41 1.73 -2.69 7.82 -1.81 -2.34 6.85 3.44 -1.48 -1.10 -6.72 -10.11 3.42 2.55 1.06 -7.41 1.15 -0.46
% of Revenue 91.31 77.29 74.34 73.39 59.85 59.39 54.80 55.10 69.89 87.62 96.86 98.93 88.22 67.61 72.65 73.62 81.00 82.45 85.48 101.12
OpEx 129 120 116 116 116 123 124 125 126 126 124 123 122 119 121 121 123 118 118 118
Change (%) -7.02 -3.59 0.23 -0.08 5.60 1.57 0.53 0.35 0.27 -1.50 -0.93 -1.12 -1.86 1.50 -0.37 2.38 -4.62 0.11 -0.03
% of Revenue 222.78 187.99 180.49 175.55 147.01 142.86 136.35 141.12 168.14 204.33 225.82 231.03 218.39 182.73 192.70 189.71 211.50 221.77 227.58 270.37
Operating Income -71 -56 -52 -50 -37 -37 -33 -36 -51 -64 -69 -70 -66 -54 -58 -57 -65 -65 -66 -74
Change (%) -21.03 -8.15 -3.27 -25.76 -0.92 -9.74 9.88 39.55 26.34 7.48 0.84 -5.49 -18.04 7.86 -2.06 14.14 -0.65 2.21 12.37
% of Revenue -122.78 -87.99 -80.49 -75.55 -47.01 -42.86 -36.35 -41.12 -68.14 -104.33 -125.82 -131.03 -118.39 -82.73 -92.70 -89.71 -111.50 -121.77 -127.58 -170.37
Interest Expense -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0 -0
Change (%) -14.95 -3.30 15.91 26.47 11.63 3.47 -6.71 -10.07 -6.40 -9.40 -9.43 9.38 17.14 24.39 17.65 3.33 -3.23 -11.67 -15.72
% of Revenue -0.18 -0.14 -0.14 -0.15 -0.16 -0.17 -0.16 -0.16 -0.17 -0.19 -0.19 -0.18 -0.19 -0.19 -0.24 -0.28 -0.32 -0.34 -0.31 -0.31
Net Income -49 -35 -31 -34 -24 -26 -22 -25 -40 -53 -56 -58 -55 -45 -50 -48 -55 -51 -51 -56
Change (%) -28.08 -13.78 9.66 -29.52 8.16 -13.00 14.33 55.65 35.26 5.34 2.71 -5.69 -16.97 11.15 -5.50 14.93 -7.54 -0.12 11.62
% of Revenue -84.93 -55.43 -47.59 -50.65 -29.91 -29.77 -24.34 -28.65 -52.94 -86.79 -102.58 -108.81 -98.10 -69.44 -80.19 -74.87 -93.70 -95.24 -97.51 -129.34

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista